Garenoxacin pharmacokinetics in subjects with renal impairment

Current Medical Research and Opinion

Volumn 23, Issue 3, 2007, Pages 649-657

  Krishna, Gopal ^a   Gajjar, Diptee ^b   Swan, Suzanne ^c   Marbury, Thomas ^d   Grasela, Dennis M ^b   Wang, Zaiqi ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

^c HENNEPIN COUNTY MEDICAL CENTER   (United States)

^d ORLANDO CLINICAL RESEARCH CENTER   (United States)

Author keywords

Dialysis; Garenoxacin; Pharmacokinetics; Renal impairment

Indexed keywords

GARENOXACIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; FEMALE; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION TEST; MALE; OPEN STUDY; PARALLEL DESIGN; RENAL REPLACEMENT THERAPY;

ADMINISTRATION, ORAL; ADULT; AGE FACTORS; AGED; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROQUINOLONES; FOLLOW-UP STUDIES; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; REFERENCE VALUES; RENAL DIALYSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 33947411699     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X167679     Document Type: Article

References (23)

1. Boswell FJ, Andrews JM, Wise R. Comparison of the in vitro activities of BMS-284756 and four fluoroquinolones against Streptococcus pneumoniae. J Antimicrob Chemother 2001;48:446-7
2. Fix AM, Pfaller MA, Biedenbach DJ, et al. Comparative antimicrobial spectrum and activity of BMS284756 (T-3811, a desfluoroquinolone) tested against 656 Enterobacteriaceae, including preliminary in vitro susceptibility test comparisons and development. Int J Antimicrob Agents 2001;18:141-5
3. Hoellman DB, Kelly LM, Jacobs MR, et al. Comparative antianaerobic activity of BMS 284756. Antimicrob Agents Chemother 2001;45:589-92
4. Malay S, Roblin PM, Reznik T, et al. In vitro activities of BMS-284756 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae. Antimicrob Agents Chemother 2002;46:517-8
5. Takahata M, Shimakura M, Hori R, et al. In vitro and in vivo efficacies of T-3811ME (BMS-284756) against Mycoplasma pneumoniae. Antimicrob Agents Chemother 2001;45:312-5
6. Takahata M, Mitsuyama J, Yamashiro Y, et al. In vitro and in vivo antimicrobial activities of T-3811ME, a novel des-F(6)-quinolone. Antimicrob Agents Chemother 1999;43:1077-84
7. Bassetti M, Dembry LM, Farrel PA, et al. Antimicrobial activities of BMS-284756 compared with those of fluoroquinolones and beta-lactams against gram-positive clinical isolates. Antimicrob Agents Chemother 2002;46:234-8
8. Schmitz FJ, Milatovic D, Boos M, et al. In vitro activity of the novel des-F(6) quinolone BMS-284756 against genetically characterized clinical streptococcal isolates, including isolates with reduced quinolone susceptibility. J Antimicrob Chemother 2002;49:698-700
9. Bello A, Stewart C, O'Mara E, et al. Absolute oral bioavailability of garenoxacin tablets and the bioequivalence of the intravenous formulation with respect to oral tablets. 37th Annual American Society of Health-System Pharmacists Midyear Clinical Meeting; December 8-12, Atlanta, GA, 2002
10. Gajjar DA, Bello A, Ge Z, et al. Multiple-dose safety and pharmacokinetics of oral garenoxacin in healthy subjects. Antimicrob Agents Chemother 2003;47:2256-63
11. Andrews J, Honeybourne D, Jevons G, et al. Concentrations of garenoxacin in plasma, bronchial mucosa, alveolar macrophages and epithelial lining fluid following a single oral 600 mg dose in healthy adult subjects. J Antimicrob Chemother 2003;51: 727-30
12. Van Wart S, Phillips L, Ludwig EA, et al. Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother 2004;48:4766-77
13. Stewart C, Gajjar D, Bello A, et al. Safety, tolerability and pharmacokinetics of BMS-284756, a novel des-F(6)-quinolone, following 28 days of once daily oral dosing in healthy subjects. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; September 22-25, Chicago, IL, 2001
14. Toussaint B, Chedin M, Bordin G, et al. Determination of (fluoro)quinolone antibiotic residues in pig kidney using liquid chromatography-tandem mass spectrometry. I. Laboratory-validated method. J Chromatogr A 2005;1088:32-9
15. Toussaint B, Chedin M, Vincent U, et al. Determination of (fluoro)quinolone antibiotic residues in pig kidney using liquid chromatography-tandem mass spectrometry. Part II: intercomparison exercise. J Chromatogr A 2005;1088:40-8
16. Hayakawa H, Fukushima Y, Kato H, et al. Metabolism and disposition of novel des-fluoro quinolone garenoxacin in experimental animals and an interspecies scaling of pharmacokinetic parameters. Drug Metab Dispos 2003;31:1409-18
17. Stass H, Kubitza D, Halabi A, et al. Pharmacokinetics of moxifloxacin, a novel 8-methoxy-quinolone, in patients with renal dysfunction. Br J Clin Pharmacol 2002;53:232-7
18. Plaisance KI, Drusano GL, Forrest A, et al. Effect of renal function on the bioavailability of ciprofloxacin. Antimicrob Agents Chemother 1990;34:1031-4
19. Fillastre JP, Montay G, Bruno R, et al. Pharmacokinetics of sparfloxacin in patients with renal impairment. Antimicrob Agents Chemother 1994;38:733-7
20. Randinitis EJ, Koup JR, Rausch G, et al. Clinafloxacin pharmacokinetics in subjects with various degrees of renal function. Antimicrob Agents Chemother 2001;45:2536-42
21. Granneman GR, Braeckman R, Kraut J, et al. Temafloxacin pharmacokinetics in subjects with normal and impaired renal function. Antimicrob Agents Chemother 1991;35: 2345-51
22. Lubasch A, Keller I, Borner K, et al. Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. Antimicrob Agents Chemother 2000;44:2600-3
23. Bello A, Hollenbaugh D, Gajjar D, et al. Ex vivo protein binding of BMS-284756: impact on the unbound AUC/MIC ratio for Streptococcus pneumoniae. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; September 22-25, Chicago, IL, 2001